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GPCRProstacyclin and its I prostanoid receptor, the IP, play central roles in hemostasis and in re-endothelialization
in response to vascular injury. Herein, intestinal and kidney enriched PDZ protein (IKEPP) was identiﬁed as
an interactant of the human (h) IP mediated through binding of PDZ domain 1 (PDZD1) and, to a lesser extent,
PDZD2 of IKEPP to a carboxyl-terminal Class I ‘PDZ ligand’within the hIP. While the interaction is constitutive,
agonist-activation of the hIP leads to cAMP-dependent protein kinase (PK) A and PKC‐phosphorylation of
IKEPP, coinciding with its increased interaction with the hIP. Ectopic expression of IKEPP increases functional
expression of the hIP, enhancing its ligand binding and agonist-induced cAMP generation. Originally thought
to be restricted to renal and gastrointestinal tissues, herein, IKEPP was also found to be expressed in vascular
endothelial cells where it co-localizes and complexes with the hIP. Furthermore, siRNA-disruption of IKEPP
expression impaired hIP-induced endothelial cell migration and in vitro angiogenesis, revealing the function-
al importance of the IKEPP:IP interaction within the vascular endothelium. Identiﬁcation of IKEPP as a func-
tional interactant of the IP reveals novel mechanistic insights into the role of these proteins within the
vasculature and, potentially, in other systems where they are co-expressed.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Post-synaptic density-95, disks-large, zonula occludens-1 (PDZ) do-
mains are amongst the most frequently occurring protein:protein
interacting domains, and act as molecular adaptors or scaffolds tomodu-
late the expression and function of a vast array of proteins in species
ranging from bacteria to man [1–3]. PDZ domains are small, modular
entities that recognize ‘PDZ ligands’ located typically, but not exclusively,
at the extreme C-termini of target proteins [1–3]. The canonical PDZ
domain contains six β-sheets (βA–βF), a short α-helix (αA), and a long
α-helix (αB) with a highly conserved ‘GLGF’ motif within its hydropho-
bic binding pocket, the so-called carboxylate binding loop (CBL), that
is essential for the sequence speciﬁc recognition of the PDZ ligand
within the target protein(s) [1–3]. The PDZ ligand itself may be groupedtransferase inhibitor; GPCR, G
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egulatory factor; PKA, cAMP-
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l rights reserved.into one of three classes according to the residues at their C-termini;
namely into Class I (Ser/Thr–X–Φ–COOH), II (Φ–X–Φ–COOH) and III
(Asp/Glu–X–Φ–COOH), where Φ represents a hydrophobic amino acid
and X can be any residue [1–3].
The Na+/H+ exchange regulatory factor (NHERF) family of
PDZ-containing proteins comprises of 4 members including NHERF1
(EBP50), NHERF2 (E3KARP), NHERF3 (PDZ domain-containing pro-
tein 1/PDZK1) and NHERF4 (intestinal and kidney enriched PDZ pro-
tein/IKEPP/PDZK2), where NHERF1/EBP50 and NHERF2 are the most
widely distributed [4,5]. Whereas NHERF1/EBP50 and NHERF2 con-
tain only two PDZ domains each, the highly homologous PDZK1 and
IKEPP each contain four PDZ domains [6,7]. IKEPP was ﬁrst identiﬁed
in the kidney and gastrointestinal (GI) tract and, thus far, its expression
has only been reported in these tissues [7–9]. In terms of its PDZdomain
structure, IKEPP is the most divergent of the NHERF family [5]. Com-
pared to the other NHERF family members, IKEPP has few known bind-
ing partners but among them include guanylyl cyclase C [7] andMAP17
[10]. IKEPP can also bind toNHE itself [11] and to a range of transporters
including the type IIa Na–Pi co-transporter [8], themultidrug resistance
protein 2 [12], the organic cation transport (OCT) family members
OCT3, OCTN1 and OCTN2 [13], to the wild-type Cl/HCO3 exchanger
down-regulated in adenoma (DRA) [14] and to the cystic ﬁbrosis trans-
membrane conductance regulator (CFTR) [15]. In all cases, the interac-
tions are dependent on PDZ domain(s) within IKEPP itself and the
individual/protein-speciﬁc PDZ ligands.
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family of arachidonic acid-derived autocoids that plays a central role in
vascular hemostasis [16,17]. It is an endothelium-derived vasodilator
and inhibitor of platelet aggregation that also exerts potent pro-
inﬂammatory and anti-proliferative effects [18–21]. In addition, prosta-
cyclin promotes angiogenesis and re-endothelialization/vascular repair,
thereby preventing restenosis in response to vessel injury [22,23].
Imbalances in the levels of prostacyclin, or of its speciﬁc synthase or
its receptor, are implicated in a range of vascular disorders including
thrombosis, stroke, myocardial infarction, atherosclerosis, systemic
and pulmonary hypertension [18,19,22]. In addition to its role in the
vasculature, prostacyclin is centrally involved in other systems includ-
ing in the kidney,where it regulates renal bloodﬂowand glomerularﬁl-
tration rate [24,25], and in the lung where it acts as a bronchodilator
and is widely implicated in the prevention of pulmonary arterial hyper-
tension [26,27].
The actions of prostacyclin are mainly mediated through ‘the I
prostanoid receptor’ or, in short, ‘the IP’ [17], a member of the G
protein-coupled receptor (GPCR) super-family. The IP is primarily
coupled to Gs/adenylyl cyclase activation, but may also regulate other
secondary effectors in a cell and/or tissue-speciﬁc manner [28–30].
The human (h)IP is somewhat unusual among GPCRs in that it un-
dergoes both farnesylation, within an evolutionarily conserved ‘CaaX’
motif located at its extreme C-terminus [30,31], and palmitoylation
at Cys308, Cys309 and Cys311 within its intracellular carboxyl-terminal
(C)-tail domain, proximal to transmembrane domain (TM) 7 [32,33].
While neither lipid modiﬁcation affect the ligand binding properties of
the hIP, they modulate its G protein coupling/intracellular signaling
and, in the case of palmitoylation, may inﬂuence the ability of the hIP
to directly interact with components of the intracellular trafﬁckingma-
chinery, including with Rab11a, to regulate agonist-induced intracellu-
lar trafﬁcking of the hIP in response to receptor activation [31–34].
In addition to their classic interaction with heterotrimeric
G-proteins, it is now recognized that GPCRs can interact with a wide
range of functionally diverse proteins known collectively as ‘GPCR
interacting proteins’ or ‘GIPs’, thereby regulating an array of other
cellular events [35,36]. Furthermore, mainly due to its divergent se-
quence and capacity to contain functionally distinct binding motifs,
the intracellular C-tail domain of the GPCR is the critical binding do-
main for such interactions between GPCRs with their speciﬁc GIP(s)
[35–37]. For example, the interaction of the hIP with its GIP, the
GTPase Rab11a, is dependent on a Rab11-binding domain (RBP) lo-
cated within the proximal C-tail domain of the hIP, the orientation
and interaction of the RBD with Rab11a may be dynamically regulat-
ed by agonist-dependent palmitoylation of the hIP at Cys309>Cys308
[33]. Furthermore, we have recently discovered that the hIP also inter-
actswith themulti-PDZ domain protein PDZK1/NHERF3, through an in-
teraction dependent on a Class I PDZ ligand located at its distal/extreme
C-terminus [38]. Herein, we report the discovery of a novel, highly
speciﬁc GIP interaction between the hIP and IKEPP, the NHERF4
family member. Hence, the overall aim of this study was to charac-
terize this interaction and to determine the inﬂuence of IKEPP on
hIP function. Data presented herein identify a novel agonist-
regulated interaction between IKEPP and the hIP that is structurally
and functionally distinct from the interaction previously identiﬁed
between the closely related PDZK1/NHERF3 [38]. Moreover, we
provide evidence that expression of IKEPP is not restricted to
renal or gastrointestinal tissue but that it is also expressed in vas-
cular endothelial cells, where it was found to play a key role in
prostacyclin-induced endothelial cell migration and in vitro angio-
genesis. The discovery that IKEPP is expressed in vascular endothe-
lial cells where it interacts with the hIP to modulate endothelial cell
migration and angiogenesis reveals a previously unknown role of
IKEPP within the vasculature as well as suggesting new insights
into the role of the hIP and IKEPP in other tissues, such as in the kid-
ney, where both proteins are co-expressed.2. Materials and methods
2.1. Materials
Cicaprost was obtained from Schering AG (Berlin, Germany).
RO1138452 was obtained from Cayman Chemicals; H-89 and Gö6983
were from Merck Biochemicals. Rabbit anti-IKEPP antibody was from
Abcam®; mouse monoclonal anti-hemaglutinin (HA) 101R antibody
was from Cambridge Biosciences; goat anti-IKEPP, normal rabbit IgG,
horseradish peroxidase (HRP)-conjugated goat anti-rabbit, rabbit anti-
goat and goat anti-mouse secondary antibodies were from Santa Cruz;
rat monoclonal anti-HA 3F10-HRP-conjugated antibody was from
Roche; rabbit anti-PhosphoSer antibody was from Invitrogen (61–
8100); recombinant human vascular endothelial growth factor (VEGF)
165 (293-VE/CF) was from R&D Systems; mouse monoclonal anti-
FLAG and anti-FLAG-HRP-conjugated M2 antibody, protein G-
sepharose and protein A-sepharose were from Sigma-Aldrich; anti-
HDJ-2 (DNAJ protein) was from Neomarkers; AlexaFluor488 goat
anti-rabbit, and AlexaFluor594 goat anti-mouse antibodies were from
Molecular Probes. Plasmids pCRE-Luc, pRL-TK and pCMVTag2C were
from Agilent Technologies. Farnesyl transferase inhibitors R115777
and SCH66336 were obtained from Janssen Pharmaceuticals and
Schering Plough, respectively. [3H]iloprost was obtained from Perkin
Elmer. All oligonucleotides were synthesized by Sigma Genosys.2.2. Subcloning and site-directed mutagenesis
The plasmids pHM6:hIPWT, pHM6:hIPSSLC and pHM6:hIPΔ383,
encoding HA epitope-tagged forms of thewild type human prostacyclin
receptor (hIP), isoprenylation defective hIPSSLC, or CaaX-truncated
hIPΔ383, respectively, have been previously described [31]. The plasmid
pHM6:hFP was generated by subcloning the full length sequence for
the human PGF2α (F) prostanoid receptor from pcDNA/Amp:hFP [39]
into the KpnI–EcoRI sites of the mammalian expression vector pHM6,
such that its coding sequence was in-frame with the HA epitope-
tag. The plasmid pcDNA3.1zeo:EP3.I, encoding the HA-tagged EP3 iso-
form of the PGE2 receptor, was a gift from Dr Barrie Ashby [40]. The
plasmids pGBKT7:hIP299–386, pGBKT7:hIP299–386,SSLC, pGBKT7:hIP320–386,
pGBKT7:hIP299–320, pGBKT7:hIP299–386,CSLS, pGBKT7:hIP299–386,CSAC,
pGBKT7:hIP299–386,CSSC, pGBKT7:hIP299–386,CALC, pGBKT7:hIP299–383,C-STOP,
pGBKT7:hIP299–383,S-STOP, pGBKT7:hIP299–386,CAAA, and pGBKT7:
hIP299–386,SAAA were previously described [34,38,41]. The plasmids
pACT2:IKEPP1–287 PDZD1⁎ and pACT2:IKEPP1–287 PDZD2⁎ were generated
by QuikChange™ site-directed mutagenesis (Agilent Technologies)
using the IKEPP library clone identiﬁed in the Y2H screen, pACT2:
IKEPP1–287, as template and the primer pairs shown in Supplemental
Table 1. The plasmid pcDNA3:IKEPP was a gift fromDr SharonMilgram,
Bethesda, MD and the plasmids pCMVTag2C:IKEPP and pACT2:IKEPP
were generated by subcloning the full-length sequence from pcDNA3:
IKEPP into the EcoRI–XhoI sites of the mammalian expression vector
pCMVTag2C or the yeast expression vector pACT2, such that its coding
sequence was in-frame for FLAG epitope-tagged or HA epitope-tagged
protein expression. The plasmids pACT:IKEPPPDZD1, pACT:IKEPPPDZD2,
pACT:IKEPPPDZD3, pACT:IKEPPPDZD4, pACT:IKEPPPDZD1–2, pCMVTag2C:
IKEPPPDZD1, pCMVTag2C:IKEPPPDZD2, pCMVTag2C:IKEPPPDZD3,
pCMVTag2C:IKEPPPDZD4 and pCMVTag2C:IKEPPPDZD1–2, encoding the
individual PDZ domains, were generated by subcloning the sequences
corresponding residues 1–165 (PDZD1), 121–255 (PDZD2), 228–400
(PDZD3), 347–505 (PDZD4) and 1–255 (PDZD1–2) of IKEPP from
pcDNA3:IKEPP into the EcoRI–XhoI sites of the yeast expression vector
pACT2 or the mammalian expression vector pCMVTag2C. The plas-
mids pCMVTag2C:IKEPPPDZD1⁎, pCMVTag2C:IKEPPPDZD2⁎, pCMVTag2C:
IKEPPPDZD3⁎, pCMVTag2C:IKEPPPDZD4⁎, pACT2:IKEPPPDZD1⁎, pACT2:
IKEPPPDZD2⁎, pACT2:IKEPPPDZD3⁎, and pACT2:IKEPPPDZD4⁎where the re-
spective hydrophobic binding pocket (“GLGF”) sequence for each PDZ
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GF167G168F to GR167E168F (Domain 2), G271FR273F274 to K271FR273E274
(Domain 3), and SYG413F414 to SYR413E414 (Domain 4), were generated
byQuikChange™ site-directedmutagenesis using pCMVTag2C:IKEPP or
pACT2:IKEPP as templates and the primer pairs shown in Supplemental
Table 1.Mutationswere designed to disrupt PDZ ligand-binding at each
domain solely through destabilization of the hydrophobic bindingpock-
et of each PDZ domain, andwere validated through the use of the online
protein domain organization tool, Pfam [43]. All mutations were con-
ﬁrmed by DNA sequence analysis.
2.3. Yeast-2-hybrid screening and yeast matings
Yeast-2-hybrid (Y2H) screening of a human kidney cDNA library
(Clontech; 3.5×106 independent clones; HY4043AH) with the carboxyl-
terminal (C-tail) domain, encoding amino acids 299–386, of the hIP
(hIP299–386) as speciﬁc bait was carried out as previously described
[33,34]. Y2H screening identiﬁed several independent clones encoding
amino acids 1–287 of IKEPP, expressed in the yeast prey plasmid
pACT2:IKEPP, as an interactant of the hIP. pGBKT7, pGBKT7:p53, encoding
the yeast GAL4 DNA binding domain (DBD) alone or as a fusionwith p53,
and pTDI, encoding the SV40 large T antigen as a fusion with the GAL4
activation domain (AD), were obtained from Clontech. All yeast protocols
were standard procedures as previously described [34,38]. For all
Y2H-based studies, the interaction of p53, encoded by pGBKT7:p53,
with its known interactant the SV40 large T antigen, encoded by pTDI,
was routinely used as an internal positive control while the absence of
an interaction of p53 with IKEPP, or its derivatives, was used to conﬁrm
that no non-speciﬁc interactions occurred.
2.4. Cell culture and transfections
Human embryonic kidney (HEK) 293 cells were obtained from
American Type Culture Collection (ATCC) and grown inminimal essen-
tial medium (MEM) containing 10% fetal bovine serum (FBS). HEK 293
cells were transiently or stably transfected using the calcium phos-
phate/DNA co-precipitation or Effectene® procedures, as previously
described [34,44]. In brief, approximately 48 h prior to transfection,
cells were routinely plated at a density of 2×106 cells per 10 cm culture
dish in 8 ml media. Thereafter, cells were transiently co-transfected
with pcDNA, pHM6 or pCMV-based vector in the presence of pADVA
[45] at a ratio of 2.5:1 using either the calcium phosphate/DNA co-
precipitation procedure, where a total of 35 μg DNA was used, or the
Effectene® (Qiagen) transfection procedure, where a total of 2 μg DNA
was used. HEK.hIP, HEK.hIPSSLC, and HEK.hIPΔ383 cells stably over-
expressing HA-tagged forms of the wild type and mutated hIPs, respec-
tively, have been described [32].
The immortalized human kidney (HK-2) cells, obtained from the
ATCC, were maintained in 1:1 Delbecco's modiﬁed Eagle's medium
(DMEM):Hams F-12 (Promocell) supplemented with insulin (5 μg/ml),
transferrin (5 μg/ml), sodium selenite (5 ng/ml), hydrocortisone
(36 ng/ml), epidermal growth factor (EGF) (10 ng/ml), tri-iodothyronine
(4 pg/ml), 2 mmol/l glutamine, and 100 U/ml penicillin and 100 μg/ml
streptomycin. The colonic epithelial Caco-2 cells were cultured with
DMEM high-glucose medium supplemented with 10% FCS. Human en-
dothelial EA.hy926 cells, obtained from the Tissue Culture Facility at
UNC Lineberger Comprehensive Cancer Centre, Chapel Hill, NC, were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM), 10% FBS
[46]. Primary (1°) human umbilical vein endothelial cells (HUVECs),
obtained from Lonza (IRT9-048-0904D), were routinely cultured in
M199media (Sigma-Aldrich) supplementedwith 0.4% (v/v) Endotheli-
al Cell Growth Supplement/Heparin (ECGS/H; Lonza), 20% (v/v) FBS
and 0.2% (v/v) L-glutamine. 1° HUVECs were used between passages 2
and 8. All mammalian cells were grown at 37 °C in a humid environ-
ment with 5% CO2 and conﬁrmed to be mycoplasma free.2.5. Immunoprecipitations
HEK.hIP, HEK.hIPSSLC and HEK.hIPΔ383 cells were transiently
co-transfected with pADVA and pCMVTag2C:IKEPP using Effectene®.
To assess the effect of the farnesyl transferase inhibitors (FTIs)
R115777 and SCH66336 on the interaction between the hIP and
IKEPP, HEK.hIP cells, transiently co-transfected with pCMVTag2C:
IKEPP, were incubated 24 h post-transfection with R115777 and
SCH66336 at concentrations indicated in the ﬁgure legends or, as a
control, with 0.1% DMSO (vehicle) for 24 h at 37 °C prior to immuno-
precipitation. The effect of the IP-selective agonist, cicaprost, on the as-
sociation of IKEPP with the hIP and the IP-mediated phosphorylation of
IKEPP were examined in HEK.hIP cells, transiently co-transfected with
pCMVTag2C:IKEPP, whereby cells were pre-incubatedwith either vehi-
cle or RO1138452 (10 μM; 10 min) prior to cicaprost stimulation, as in-
dicated. To assess the effect of the kinase inhibitors, H-89 and Gö6983,
on the interaction between the hIP and IKEPP, HEK.hIP cells, transiently
co-transfected with pCMVTag2C:IKEPP, were incubated 48 h post-
transfection with H-89 and Gö6983 at concentrations indicated in the
ﬁgure legends or, as a control, with 0.1% DMSO (vehicle) for 10 min at
37 °C prior to immunoprecipitation or stimulation with cicaprost as in-
dicated. Primary (1°) HUVECswere plated onto 10 cmdishes to achieve
>80% conﬂuence. In all cases prior to immunoprecipitation, cells were
washed in the appropriate serum-free media and either incubated
with vehicle or with 1 μM cicaprost for the times indicated in the ﬁgure
legends. Thereafter, cells were washed, lysed and clariﬁed as per previ-
ously detailed protocols [33,34]. HA-tagged forms of the hIP, PGF2α
receptor (FP) or EP3-subtype of the PGE2 receptor (EP) were immu-
noprecipitated using anti-HA (101R; 1:300) antibody; FLAG-tagged
IKEPP was immunoprecipitated with anti-FLAG M2 (1:200); endoge-
nously expressed hIP was immunoprecipitated with the afﬁnity puri-
ﬁed rabbit polyclonal anti-hIP (1:50) antibody [33] or, as negative
controls, with normal rabbit IgG (Santa Cruz). Thereafter, lysates were
incubated for 1 h with either a 50% slurry of protein G-sepharose
(10 μl) or protein A-sepharose (10 μl) prior to repeated washing with
radioimmune precipitation buffer (RIP; 50 mM Tris–Cl, pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40 (v/v), 0.5% sodium deoxycholate
(w/v), 0.1% SDS (w/v), 10 mM sodium ﬂuoride, 25 mM sodium pyro-
phosphate, 1 μg/ml leupeptin, 0.5 mM phenylmethylsulfonyl ﬂuoride
and 1 mM sodium orthovanadate) followed by PBS (2–3 times). Immu-
noprecipitateswere resolved by SDS-PAGEand subjected to immunoblot-
ting with either anti-FLAG (1:1000), anti-HA (3F10; 1:500), anti-IKEPP
(1:500), anti-HDJ-2 (1:4000), and/or anti-PhosphoSer (1:1000) anti-
bodies, as indicated.
2.6. Immunohistochemistry
Normal human kidney tissue blocks, formalin-ﬁxed and parafﬁn-
embedded, were obtained through ethical consent from St Vincent's
University Hospital, Dublin, Ireland. Tissue sections were cut at
4 μm thickness and baked onto slides at 50–56 °C for up to 60 min.
Prior to immunolabelling, sections were dewaxed in two changes of
xylene (2×10 min) and rehydrated through a series of decreasing al-
cohol solutions (100%, 5 min×2; 95%, 1 min; 80%, 1 min) before
being washed in distilled water. Endogenous peroxidase activity
was blocked by incubating the tissue sections in 3% hydrogen perox-
ide, prepared in methanol, for 10 min at room temperature, followed
by repeated washing of slides in PBS. Thereafter, non-speciﬁc binding
was blocked by incubating the tissue sections for 30 min at room
temperature with 1% horse serum in PBS (blocking buffer) to which
Avidin D (4 drops per ml of blocking buffer; Vector Labs Avidin/Biotin
Blocking Kit) was added to block endogenous biotin. Sections were
then incubated with primary (1°) antibody, prepared in blocking
buffer and containing biotin (4 drops per ml of blocking buffer; Vec-
tor Labs Avidin/Biotin Blocking Kit), where rabbit anti-hIP [33] and
rabbit anti-IKEPP (Abcam®) antibodies were used at 10–12 μg/ml.
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the primary antibodies, sections were washed in PBS, prior to incuba-
tion for 30 min with biotinylated universal secondary antibody (1:50
dilution; Vectastain Universal Elite ABC kit), prepared in blocking
buffer. After washing, tissue sections were incubated with Vectastain
ABC reagent, as per manufacturer's instructions, followed by incuba-
tion of tissue sections with the chromogen 3,3′-diaminibenzidine
(DAB) substrate (0.05% DAB, 0.015% hydrogen peroxide in PBS) for
5–10 min. Tissue sections were counterstained with hemotoxylin,
dehydrated through increasing alcohol series and xylene (2×10 min)
prior to mounting in DPX. Slides were imaged using a Zeiss microscope
and Axiovision software.
2.7. Immunoﬂuorescence microscopy
To examine the localization of IKEPP and the hIP, HEK.hIP cells
transiently co-transfected with pCMVTag2C:IKEPP plus pADVA were
grown on poly-L-lysine treated coverslips in 6-well plates for at
least 48 h post-transfection. Thereafter, essentially as previously
described [38], cells were ﬁxed and permeabilized prior to immuno-
labelling with the afﬁnity puriﬁed rabbit polyclonal anti-hIP antibody
(1:500; 1% BSA in TBS) or anti‐IKEPP (1:500; 1% BSA in TBS) for 1 h at
RT followed by AlexaFluor488 goat anti-rabbit IgG secondary anti-
body (1:2000; 1% BSA in TBS) or AlexaFluor594 rabbit anti-mouse
IgG secondary antibody (1:4000; 1% BSA in TBS), to detect the IP re-
ceptor or IKEPP respectively. Imaging was carried out using the
Zeiss Axioplan 2 microscope and Axioplan Version 4.4 imaging soft-
ware. Data presented are representative images of at least three inde-
pendent experiments from which at least 10 ﬁelds were viewed at
63× magniﬁcation, where the horizontal bar represents 10 μM.
2.8. Radioligand binding assays
To examine the effect of IKEPP on hIP expression, HEK.hIP cells
were transiently co-transfected with pCMVTag2C:IKEPP in the pres-
ence of pADVA or, as a control, with pCMVTag2C. Radioligand binding
assays (RLBAs; saturation binding studies and Scatchard analyses) of
the hIP were carried out as previously described [31,38].
2.9. Measurement of agonist-induced cAMP generation
A gene reporter-based assay was performed to investigate the
effect of over-expression of IKEPP on changes in intracellular cAMP
levels in response to stimulation of the hIP with its selective ago-
nist cicaprost, essentially as previously described [47]. In brief, the
plasmids pHM6:hIP (1.5 μg), pCMVTag2C:IKEPP (2 μg), pCMVTag2C:
IKEPPPDZD1⁎ (2 μg), pCMVTag2C:IKEPPPDZD2⁎ (2 μg), pCMVTag2C:
IKEPPPDZD3⁎ (2 μg), pCMVTag2C:IKEPPPDZD4⁎ (2 μg) or, as a negative
control, pCMVTag2C, were each transiently co-transfected into HEK
293 cells with the luciferase reporter pCRE-Luc (1 μg), pRL-TK (50 ng)
and pADVA (0.5 μg) using Effectene® reagent as per themanufacturers'
instructions (Qiagen). Cells were treated 72 h post-transfection with
3-isobutyl-1-methylxanthine (IBMX; 100 μM) at 37 °C for 30 min and
then stimulated with either vehicle (V; 0.01% DMSO) or 1 μM cicaprost
at 37 °C for 3 h. Fireﬂy and renilla luciferase activity was assayed 76 h
post-transfection using the Dual Luciferase Assay System®. Relative
ﬁreﬂy to renilla luciferase activities (arbitrary units) were calculated
as a ratio and were expressed in relative luciferase units (RLU).
2.10. Disruption of IKEPP expression by small interfering (si)RNA
For small interfering (si)RNA experiments, 1° HUVEC cells were
plated at ~2.5×105 cells/35‐mmplate and some 24 h prior to transfec-
tion such that cells reach ~50% conﬂuence. Thereafter, cells were
transfected with 30 nM IKEPP siRNA (siRNAIKEPP; 5′-GCAAGUGGGAGA-
CGUGAUUtt-3′; Dharmacon), 30 nM Lamin A/C siRNA (siRNALaminA/C;5′-CUGGACUUCCAGAAGAACAtt; Qiagen) or 30 nM scrambled nega-
tive control siRNA (siRNACONTROL; 5′-AATTCTCCGAACGTGTCACGTtt-3′;
Qiagen) using RNAiFECT transfection reagent (Qiagen), as permanufac-
turer's instructions. To conﬁrm the efﬁcacy of the siRNA to disrupt IKEPP
expression, following transfection 1° HUVECs were harvested after
incubation at 0–72 h and subject to SDS-PAGE (10–15 μg/lane on
10% polyacrylamide gels) followed by electroblotting onto PDVF mem-
branes (Roche). Membranes were successively screened using anti-
IKEPP (1:1000dilution; Santa Cruz) and anti-LaminA/C (1:500dilution;
Santa Cruz) antibodies and then screened using anti-HDJ-2 (1:4000 di-
lution; Neomarkers) antibody to conﬁrm uniform protein loading. For
migration and tube formation assays, 24 h post-siRNA transfection
cells were placed in reduced serum growth media (2.5% FBS) for 16 h
before experiments were performed.
2.11. Cell migration assays
In order to monitor changes in 1° HUVEC migration, scratch wound
assays were performed essentially as previously described [38] where
cells were pre-incubated with either vehicle (0.01% PBS), cicaprost
(1 μM) or VEGF (50 ng/ml) and wound closure assessed 12 h post-
injury. Reduction in scratch paths were visualized and imaged using
a Nikon TMS inverted microscope with Matrox Intellicam software
(Version 2.07) and analyzed with TScratch software (Version 1.0).
Migration was expressed as mean (±S.E.M.) percentage of basal cell
migration, where at least three independent experiments were per-
formed in triplicate.
2.12. In vitro tube formation assays
Matrigel tube formation assays were performed to assess in vitro
angiogenesis essentially as previously described [38] where tube for-
mation in 1° HUVECs stimulated with either vehicle (0.01% PBS),
cicaprost (1 μM) or VEGF (50 ng/ml) was examined. After 12 h incu-
bation, cell morphology was visualized and imaged at 40× magniﬁca-
tion using a Nikon TMS inverted microscope with Matrox Intellicam
software (Version 2.07; 4 times at random per ﬁeld). The length of
tube was measured with WCIF ImageJ software (Version 1.37c) and
expressed as mean (±S.E.M.) percentage of basal tube length,
where at least three independent experiments were performed in
triplicate.
2.13. Data analyses
Statistical analyses of differences were carried out using 1-way or
2-way ANOVA followed by post-hoc Dunnett's multiple comparison
t tests, as indicated, throughout employing GraphPad Prism, version
4.00 package. P-values of less than or equal to 0.05 were considered
to indicate a statistically signiﬁcant difference. As relevant, single,
double and triple symbols signify P≤0.05, ≤0.01 and ≤0.001, respec-
tively, for post-hoc Dunnett's multiple comparison t-test analyses.
3. Results
3.1. Identiﬁcation of IKEPP as an interactant of the hIP
We recently identiﬁed Rab11a [33,34] and PDZK1 [38] as GPCR
interacting proteins/GIPs that directly and speciﬁcally interact with
the hIP involving unique binding domains within its proximal and
distal C‐tail region, respectively. While Rab11a binds to a 14-residue
Rab11a binding domain (RBD), comprising Val299–Val307 and adja-
cent to the palmitoylated residues Cys308–Cys311, located within the
proximal C-tail domain of the hIP [33], the interaction of PDZK1 is de-
pendent on the three C-terminal residues of the hIP corresponding to
a class I PDZ ligand [38]. Herein, we report the identiﬁcation of intes-
tinal and kidney enriched PDZ protein (IKEPP), the fourth member of
2002 H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012the Na+/H+ exchange regulatory factor (NHERF) family of intracellu-
lar multi-PDZ domain adaptor proteins, as a direct interacting partner
of the hIP. Speciﬁcally, using the C-tail domain (hIP299–386) of the hIP
as the initial bait protein, yeast-two-hybrid (Y2H) screening of a
human kidney cDNA library identiﬁed several independent clones
encoding amino acids 1–287 of IKEPP (IKEPP1–287), encompassing
its entire PDZ domains 1 (PDZD1) and 2 (PDZD2; Fig. 1A) as interac-
tants of the hIP.
To further characterize the interaction, extended Y2H matings
were performed using IKEPP1–287 and various subfragments derived
from the C-tail domain of either the wild-type (hIP299–386,WT or
hIP320–386,WT), the isoprenylation-defective (hIP299–386,SSLC) forms of
the hIP, or a subfragment corresponding to the RBD of the hIP
(hIP299–320) alone (Fig. 1A). While each of the bait and prey strains
mated successfully to form diploids (Fig. 1A, DDO), IKEPP1–287 only
interacted with the subfragments containing the C-terminal residues
of the hIP domain (hIP299–386 and hIP320–386; Fig. 1A, QDO). Converse-
ly, IKEPP1–287 did not interact with the hIP299–320 fragment (Fig. 1A,80 kDa
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Fig. 1. Interaction of IKEPP with the human prostacyclin receptor. Panel A: Schematic of the ful
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type hIP (−C383SLC; e.g., in hIP299–386,WT or hIP320–386,WT) or an
isoprenylation-deﬁcient variant associated with the hIPSSLC(−S383SLC;
e.g., in hIP299–386,SSLC). These data conﬁrm that IKEPP1–287 speciﬁcally
interacts with the C-tail domain of the hIP.
Thereafter, the ability of full-length IKEPP (IKEPP1–505, herein-
after referred to as IKEPP) to speciﬁcally interact with hemagglutinin
(HA)-epitope tagged forms of either the wild-type hIP, hIPSSLC or
hIPΔ383 expressed in the previously characterized mammalian
HEK.hIP, HEK.hIPSSLC, and HEK. IPΔ383 cell lines [32] were examined
through co-immunoprecipitation studies (Fig. 1B). FLAG-tagged
IKEPP was detected in anti-HA immunoprecipitates from cells ex-
pressing either the wild type hIP or isoprenylation-deﬁcient hIPSSLC
and at similar levels in both cases (Fig. 1B, upper panel). In contrast,
only trace amounts of IKEPP was co-immunoprecipitated with theDDO QDODDO QDO
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Fig. 2. Characterization of the PDZ ligand within the C-tail domain of the hIP and iden-
tiﬁcation of the PDZ domains within IKEPP involved in the interaction with the hIP.
Panel A: S.c. Y187 (pACT2.IKEPP1–287) or, as a control, S.c. Y187 (pTDI-I) prey strains
were mated with the S.c. AH109 (pGBKT7.hIP299–386) bait strains (encoding either
wild type (WT) or variants of hIP299–386, where the −C383SLC386 carboxyl-terminal
residues corresponding to the positions (P)0, P-1, P-2, and P-3 of its PDZ ligand were
mutated as indicated) or, as controls, p53 or the vector (pGBKT7) alone. Panel B: Sche-
matic showing full length IKEPP and the sub-fragments, encoding its individual PDZ
domains PDZD1–PDZD4, generated for this study. Panel C: S.c. Y187 (pACT2) expressing
the listed IKEPP sub-fragments encoding individual or paired PDZ domains, as indicat-
ed, were mated with S.c. AH109 (pGBKT7) encoding the listed hIP subfragments and, as
controls, p53 or the vector pGBKT7 alone. Diploids were selected on DDO medium,
whereas interactants were selected on QDO medium. Data; n≥3.
2003H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012hIPΔ383, a variant of the hIP lacking the extreme C-terminal amino acids
including its entire CaaX box (Fig. 1B, upper panel). Furthermore, IKEPP
was not detected in the anti-HA:FP or anti-HA:EP3 immunoprecipitates
from the control HEK 293 cell lines over-expressing HA-tagged forms
of the prostaglandin (PG)F2α receptor (the FP) or the EP3 subtype
of the PGE2 receptor (Fig. 1C, upper panel). Such differences in co-
immunoprecipitation of IKEPP with the various HA-tagged receptors
used were not due to failure or variations in the immunoprecipitations
per se (Fig. 1B and C,middle panels) or due to differences in the levels of
FLAG-tagged IKEPP expressed in the cell lysates employed in the indi-
vidual immunoprecipitations (Fig. 1B and C, lower panels).
To further investigate thepossible inﬂuenceof the isoprenylation sta-
tus of the hIP on its interaction with IKEPP, the effect of inhibition of
farnesylation of the hIP following incubation of HEK.hIP cellswith the se-
lective farnesyl transferase inhibitors (FTIs) R115777 or SCH66336 was
examined (Fig. 1D, upper panel). As controls for these studies, the ability
of the FTIs to inhibit general protein farnesylation was conﬁrmed
whereby both agents efﬁciently inhibited farnesylation of the molecular
chaperone protein HDJ-2, as evidenced by the presence of the non-
farnesylated (49 kDa) in addition to the farnesylated (45 kDa) species
of HDJ-2 in the presence of the FTIs while only the farnesylated
species was present in their absence (Fig. 1C, lower panel). Neither
R115777 nor SCH66336 treatment affected the level of IKEPP co-
immunoprecipitated with the hIP (Fig. 1D, upper panel).
Taken together, these data identify a novel interaction between
IKEPP and the hIP in both yeast and mammalian cells. Furthermore,
while the interaction requires the presence of the C-terminal residues
of the hIP, it appears to be independent of the isoprenylation status of
the hIP per se.
3.2. Characterization of the PDZ ligand and identiﬁcation of the PDZ
interacting domains
PDZ ligands at the extreme C-termini of target proteins typically
belong to one of three Classes I–III, depending on the sequence com-
position of the 3 terminal residues [3]. Through its interaction with
PDZK1, the C-terminal residues of the hIP were previously identiﬁed
as a Class I PDZ ligand, with the typical Ser/Thr–X–Φ–COOH consen-
sus sequence [38]. Herein, Y2H-based interaction studies were used
to re-examine the PDZ ligand determinants of the hIP involved in its
interaction with IKEPP1–287. To this end, the importance of residues
at the P0, P-1, P-2, and P-3 of the PDZ ligand involved in the interaction
of the hIP with IKEPP1–287 was investigated by mutation of those res-
idues to corresponding Ser or Ala residues, either alone or in combi-
nation (Fig. 2A).
As previous, each of the bait and prey strains mated successfully to
form diploids (Fig. 2A, DDO panels). Speciﬁc mutations of the hIP at
the P-1 (hIP299–386,CSAC, a variant not predicted to be isoprenylated,
or hIP299–386,CSSC, a variant predicted to be isoprenylated) and at the
P-3 positions (hIP299–386,SSLC) did not affect their ability to interact
with IKEPP1–287. Conversely, mutation at the P0 (hIP299–386,CSLS) abol-
ished the interaction, whereas mutation at the P-2 (hIP299–386,CASC)
substantially reduced the interaction with IKEPP (Fig. 2A, QDO panels).
Moreover, combined mutation of the P0, -1, -2 (hIP299–386,CAAA),
P0, -1, -2, -3 (hIP299–386,SAAA) or deletion of P0, -1, -2 (hIP299–386,C-stop or
hIP299–386,S-stop) generated forms of the hIP that did not interact with
IKEPP. Collectively, these data reafﬁrm that the C-terminal residues of
the hIP act as a Class I PDZ ligand, where the C-terminal Cys386 at P0
and Ser384 at P-2 are obligate for its interactionwith IKEPP anddata herein
is in complete agreement with that previously obtained from studies in-
volving the interaction of the hIP with PDZK1 [38].
Similar to PDZK1, IKEPP is a member of the NHERF family con-
taining 4 PDZ domains, referred to hereinafter as PDZD1, PDZD2,
PDZD3 and PDZD4 (Fig. 2B). While the original Y2H screen initially
identiﬁed IKEPP1–287, comprising PDZD1 and PDZD2, as the speciﬁc in-
teractant of the hIP, it was sought to establish whether PDZD1 and/orPDZD2 or indeed whether the other PDZD3 and/or PDZD4 domains may
also contribute to the interaction with the hIP. To this end, the
Y2H-based approach was used to examine the interaction of the
hIP299–386 and its derivatives, as listed, with subfragments of IKEPP
encoding its individual PDZD1, PDZD2, PDZD3, PDZD4 or combined
PDZD1–D2 domains (Fig. 2B and C). Only subfragments of IKEPP
containing PDZD1, namely PDZD1 alone or PDZD1–D2, showed a speciﬁc
interaction with the hIP derivatives (hIP299–386 WT, hIP299–386 SSLC and
hIP320–386 WT) while the PDZD2, PDZD3 or PDZD4 subfragments failed
to show any interaction (Fig. 2C, QDO). Furthermore, as expected,
none of the PDZ domains of IKEPP interacted with the RBD of the
hIP299-386,WT
hIP299-386,SSLC
hIP320-386,WT
hIP299-320
pGBKT7
p53
QDO DDO
B)
C)
0
20
40
60
80
100
120
R
el
at
iv
e 
IK
EP
P 
as
so
ci
at
io
n 
(%
)
**
*
58kDa
46kDa
58kDa
80kDa
80kDa
IP: anti-HA (101R)
IB: anti-FLAG 
IP: anti-HA (101R)
IB: anti-HA (3F10)
IB: anti-FLAG
IKEPP
50 127 158 232 343264 479402
(31) (32) (59) )62()05(
5051
PDZD1* 5051
5051
5051
5051
PDZD2*
PDZD3*
PDZD4*
PDZD1 PDZD2 PDZD3 PDZD4
PDZD1* PDZD2 PDZD3 PDZD4
PDZD1 PDZD2* PDZD3 PDZD4
PDZD1 PDZD2 PDZD3* PDZD4
PDZD1 PDZD2 PDZD3 PDZ
D4*
A)
Fig. 3. Identiﬁcation of the PDZDomainswithin IKEPP Involved in the Interactionwith the
hIP. Panel A: Schematic of full length IKEPP with its 4 PDZ domains whereby the ‘GLGF
motif’ mutated within each of the individual PDZD1–PDZD4 domains are indicated by an
asterisks (*). Panel B: S.c. Y187 (pACT2.IKEPP) prey strains, encoding the full length
IKEPP where the ‘GLGF motif’ in each of the PDZD1–PDZD4 domains are mutated
(*; Panel B), as indicated, were mated with S.c. AH109 (pGBKT7) encoding the listed hIP
subfragments and, as controls, p53 or the vector pGBKT7 alone. Diploids were selected
on DDO medium, whereas interactants were selected on QDO medium. Data; n≥3.
Panel C: HEK.hIP cells were transiently transfected with pCMVTag2C plasmids encoding
FLAG-tagged forms of IKEPP, IKEPPPDZD1⁎, IKEPPPDZD2⁎, IKEPPPDZD3⁎ and IKEPPPDZD4⁎.
After 48 h, HA-tagged hIP was immunoprecipitated with anti-HA 101R antibody and im-
munoprecipitates (IP) were immunoblotted (IB) with anti-FLAG-IKEPP (upper panel) or
anti-HA 3F10 (middle panel) antisera. Uniform expression of the FLAG-tagged IKEPP pro-
teins was veriﬁed by immunoblot analysis of whole cell lysates (50 μg/lane) with
anti-FLAG antibody (lower panel). The bar chart shows mean relative levels of the wild
type and mutated forms of IKEPP associated with the anti-HA 101R immunoprecipitates
(relative protein, %±S.E.M., n=3), where levels of the wild-type IKEPP are expressed as
100%. The asterisks indicate where mutation of the GLGF sequence within the individual
PDZ domains of IKEPP resulted in signiﬁcant reductions in levels of IKEPP found in
anti-HA:hIP precipitates, where ** and * indicate Pb0.01 and Pb0.05, respectively, for
post-hoc Dunnett's multiple comparison t-test analysis.
2004 H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012hIP (hIP299–320) or with other control proteins, including p53 or that
encoded by the vector alone (Fig. 2C, QDO). These data suggest that
PDZD1 plays a critical role in the interaction of IKEPP with the hIP.
The folding pattern of domains within proteins, in particular in
those with multiple domains, may be inﬂuenced by the presence of
those other domains [48]. Hence, it is theoretically possible that fail-
ure to observe an interaction between the PDZ ligand of the hIP
with the individual PDZD2, PDZD3 or PDZD4 domains of IKEPP may
simply be due to altered folding or indeed due to misfolding. Hence,
as an additional, independent means of identifying the PDZ do-
main(s) of IKEPP involved in its interaction with the hIP, the effect
of mutation of the critical residues within the ‘GLGF’ motif of the car-
boxylate binding loop (CBL)/hydrophobic binding pocket of each of
the individual PDZD1, PDZD2, PDZD3 or PDZD4 domains on the interac-
tion of full length IKEPP with the PDZ ligand of the hIP was investigat-
ed (Fig. 3A and B). Consistent with previous data (Fig. 2C), mutation
of the ‘GLGF’ motif in PDZD1 completely abolished the interaction of
IKEPPPDZD1⁎ with all the hIP subfragments containing a functional
PDZ ligand (Fig. 3B, QDO). Conversely, mutation of the ‘GLGF’ motifs
in PDZD2 (IKEPPPDZD2⁎), PDZD3 (IKEPPPDZD3⁎) or PDZD4 (IKEPPPDZD4⁎)
did not affect the interaction (Fig. 3B, QDO). Furthermore, speciﬁc
mutation of the ‘GLGF’ motifs within the individual PDZD1 and
PDZD2 domains present in IKEPP1–287, the original Y2H interactant,
conﬁrmed that disruption PDZD1, but not PDZD2, abolished the inter-
action with the PDZ ligand of the hIP (data not shown).
As an additional means of identifying the PDZ domain(s) involved in
the interaction, the effect of mutating the ‘GLGF’motifs within the indi-
vidual PDZD1, PDZD2, PDZD3 or PDZD4 domains on the interaction of full
length IKEPP with the hIP expressed in mammalian HEK 293 cells was
investigated through co-immunoprecipitations. In agreement with pre-
vious data (Fig. 1B–1D), IKEPP co-precipitated in immune-complexes
with the hIP (Fig. 3C, upper panel). Disruption of the ‘GLGF’motifwithin
PDZD1⁎ (Pb0.001) and, to a lesser extent, within PDZD2⁎ (Pb0.05) led to
signiﬁcant reductions in the interaction of IKEPP with the hIP as
evidenced by the reduced level of IKEPP present in the anti-HA:hIP im-
mune complexes (Fig. 3C, upper panel). Conversely, disruption of the
‘GLGF’ motifs within PDZD3⁎ or PDZD4⁎ did not affect the interaction of
IKEPP with the hIP (Fig. 3C, upper panel). Any differences in levels of
IKEPP in the immune-complexeswas not due variations in levels of pre-
cipitation of the hIP per se, or indeed due to differences in the expression
of IKEPP or its derivatives in the cell lysates (Fig. 3C, middle and lower
panels, respectively).
Collectively these data conﬁrm that hIP contains a Class I PDZ li-
gand at its C-terminus and identify a critical role for PDZD1 and, to a
lesser extent, for PDZD2 of IKEPP in the interaction with the hIP.
3.3. Effect of IKEPP on the expression and signaling of the hIP
PDZ containing proteins, including IKEPP, have been shown to affect
the expression and/or function of certain of their targets, and in a
protein and/or cell type-speciﬁc manner [7,10,13,49]. Having es-
tablished that IKEPP acts as a direct interactant of the hIP, its effect on
the expression and signaling of the hIP in the clonal HEK.hIP cell line
was investigated. Although immunoblot analysis suggested that
ectopic expression of IKEPP did not affect the overall level of hIP ex-
pression per se in HEK.hIP cells (Fig. 4A, IKEPP; P=0.70), saturation
radioligand binding assays showed that over-expression of IKEPP led
to a 1.7-fold increase in binding of the IP radioligand [3H]iloprost in
crude membrane preparations (Fig. 4A, IKEPP; Pb0.01). Furthermore,
Scatchard analysis established that expression of IKEPP led to an
~2-fold increases in maximal Iloprost binding (Bmax) by the hIP with-
out affecting the binding afﬁnity (Kd) per se (2.08±0.72 nM, Pb0.72,
high afﬁnity binding site; 24.45±0.50, Pb0.40, low afﬁnity binding
site; [50]), suggesting that IKEPP may be enhancing the expression of
functionally mature hIP, rather than increasing its overall expression.
These ﬁndings were corroborated by ﬂow cytometric analysis wherebyit was established that the relative ﬂuorescence intensity due to anti-HA
hIP analysis was unaltered in the presence of IKEPP compared to control
cells (Supplemental Fig. 1A). This is in direct contrast with that of the
control protein PDZK1 which, in agreement with previous reports
[38], led to ~1.4 fold increase in expression of the hIP (Supplemental
Fig. 1A). Furthermore, the level of hIP‐induced cAMP generation in re-
sponse to stimulation with the selective agonist cicaprost was signiﬁ-
cantly increased in HEK.hIP cells following over-expressing IKEPP
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Fig. 4. Effect of IKEPP on the expression and signaling of the hIP. Panels A and C: HEK.hIPWT cells were transiently transfected with pCMVTag2C plasmids encoding FLAG-tagged forms of
IKEPP, IKEPPPDZD1⁎, IKEPPPDZD2⁎, IKEPPPDZD3⁎ or IKEPPPDZD4⁎ or, as a control, with the vector alone (Ø). Radioligand binding analysis was performed 72 h post-transfection in the presence
of 4 nM [3H]iloprost for 60 min using crude membrane (P100) fractions. Data are presented as fold increases in [3H]iloprost bound where levels in the presence of empty vector (Ø) are
expressed as 1. Expression of IKEPP and the hIP was conﬁrmed by immunoblot analysis with anti-FLAG (upper panel) and anti-HA 3F10 (lower panel) antisera (panel A). The bar chart
showsmean relative levels of theHA-tagged hIP expression in the presence of empty vector (Ø) or IKEPP (Mean±S.E.M., n=3), where levels of the hIP in the presence of vector alone are
expressed as 1. Panels B and D: HEK293 cells were transiently co-transfected with pHM6:hIP, pADVA, pCRE-LUC and pRL-TK in the presence of vector encoding FLAG-tagged forms of
IKEPP, IKEPPPDZD1⁎, IKEPPPDZD2⁎, IKEPPPDZD3⁎, or IKEPPPDZD4⁎ or, as a control, with the vector alone (Ø). Cells were incubated either with vehicle or cicaprost (1 μM; 3 h) prior to determi-
nation of cAMP generation, where data are represented asmean cAMP generation (RLU; panel B, left panel) or fold inductions in agonist-induced cAMPaccumulation (panel B, right panel
and panel D). Transfection efﬁciency was conﬁrmed through immunoblot analysis of the whole cell lysates (35 μg/lane) with anti-IKEPP antibody (panel B, inset). The asterisks indicate
signiﬁcant increases in radioligand binding or cAMP generation in thepresence of IKEPP, or itsmutated variants, compared to that in the presence of the vector (Ø) alone,where ***, **, and
* indicate Pb0.001, Pb0.01 and Pb0.05, respectively, for post-hoc Dunnett's multiple comparison t-test analysis.
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suggest that ectopic expression of IKEPP leads to an increase in the ex-
pression of functionally active hIP, without affecting its overall expres-
sion levels per se.
As a means of validating that such effects of IKEPP are due to a
PDZ-domain type interaction with the hIP, the effect of disruption of
the ‘GLGF’ motif in each of the individual PDZ domains of IKEPP on
[3H]iloprost binding and cicaprost-induced cAMP generation by the
hIP expressed in HEK.hIP cells was investigated. Disruption of the
‘GLGF’ motif in PDZD1 (IKEPPPDZD1⁎) completely abolished the IKEPP-
induced increase in both radioligand binding (Fig. 4C) and cicaprost-
induced cAMP generation (Fig. 4D) by the hIP. Moreover, disruption
of the ‘GLGF’ motif in PDZD2 (IKEPPPDZD2⁎) also reduced the increase
in both [3H]iloprost binding and cicaprost-induced cAMP generation,
albeit to a lesser extent than with IKEPPPDZD1⁎ (Fig. 4C and D). In con-
trast, disruption of the ‘GLGF’ motifs in either PDZD3 or PDZD4 did not
have a signiﬁcant effect on the IKEPP-induced increases in either
radioligand binding or cAMP generation by the hIP (Fig. 4C and D).
Hence, taken together, these data conﬁrm that IKEPP leads to an in-
crease in the functional expression of the hIP and provide further evi-
dence that PDZD1, and to a lesser extent PDZD2, are the PDZ domainsresponsible for mediating the interaction between IKEPP and the hIP
in mammalian cell lines.
3.4. Effect of agonist-activation of the hIP on its interaction with IKEPP
To investigate the possible inﬂuence of agonist activation of the hIP
on its interactionwith IKEPP, the effect of cicaprost-stimulationwas ex-
amined through co-immunoprecipitations in HEK.hIP cells. Consistent
with previous data (Fig. 1B–1D), in the absence of agonist, IKEPP was
readily detected in immune-complexes with the anti-HA.hIP (Fig. 5A,
upper panel). In response to cicaprost stimulation, the level of IKEPP
in the anti-HA.hIP immunoprecipitates was signiﬁcantly increased
(Fig. 5A, upper panel; 1 μM, 10 min; P=0.0079), an effect that was ab-
rogated by the pre-incubation ofHEK.hIP cellswith thehighly speciﬁc IP
antagonist RO1138452 (Fig. 5A, upper panel; 10 μM, 10 min). Such dif-
ferences in the levels of IKEPP in the anti-HA.hIP immunoprecipitates
were not due differences in the efﬁciency of the immunoprecipitation
per se (Fig. 5A; middle panel) or due to substantial differences in
IKEPP expression in the cell lysates (Fig. 5A; lower panel).
Many PDZ domain-containing proteins, including IKEPP and other
members of the NHERF family are phosphoproteins and, in several
2006 H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012cases, phosphorylation is thought to play a role in regulating the in-
teraction of the PDZ domain protein with its given target(s)
[5,51,52]. Furthermore, somewhat similar to that observed herein in-
volving IKEPP, the interaction of the hIP with PDZK1/NHERF3 has also
been established to be regulated in an agonist-dependent manner
and, more speciﬁcally, this regulated interaction occurs through a
mechanism involving direct IP-induced cAMP-dependent protein ki-
nase (PK)A-phosphorylation of PDZK1 at Ser505 [38]. Hence, to inves-
tigate if the agonist-regulated interaction of IKEPP with the hIP may
actually involve alterations in the phosphorylation status of IKEPP,
the effect of cicaprost stimulation on the phosphorylation of IKEPP
was investigated employing an anti-PhosphoSer‐speciﬁc antibody
(Fig. 5B). Under basal conditions, in the absence of agonist, the level
of phosphoSer detected in the anti-FLAG:IKEPP immunoprecipitates
was minimal (Fig. 5B, upper panel). In response to cicaprost stimula-
tion of the hIP (1 μM, 10 min), there was a substantial increase in
IKEPP phosphorylation as evidenced by increased level of phosphoSer
detected in the anti-FLAG:IKEPP precipitates (Fig. 5B, upper panel,
Pb0.0001). Conﬁrmation that the enhanced cicaprost-induced phos-
phorylation of IKEPP is mediated through activation of the hIP was
established whereby the selective IP antagonist RO1138452 impaired
the cicaprost-induced phosphorylation of IKEPP (Fig. 5B, upper panel,
P=0.002). Furthermore, immunoblotting of the anti-FLAG immuno-
complexes conﬁrmed that the observed differences in the anti-
PhosphoSer signal was not due to variations in the efﬁciency of the
immunoprecipitation of IKEPP per se (Fig. 5B, lower panel).
Hence, these data establish that the interaction of IKEPPwith the hIP
is increased in response to receptor activation, an effect that coincides
with increased hIP-dependent phosphorylation of IKEPP. As stated,
the hIP is primarily coupled to Gs/adenylyl cyclase and, in turn, to
downstream cAMP dependent protein kinase (PK)A activation but can
also couple to Gq/phospholipase (PL)Cβ PKC activation [28,30]. There-
fore, in view of the agonist-regulated interaction of IKEPP with the hIPB)
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Fig. 5. Effect of agonist-activation of the hIP on the interactionwith IKEPP. Panels A and B: HEK.hIP
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mean relative levels of the phosphoserine associated with the anti-FLAG immunoprecipitates
RO113852 are expressed as 100%. Asterisks indicate a signiﬁcant change in levels of IKEPP presen
tions where ****, ** and * indicates Pb0.0001, Pb0.01 and Pb0.05, respectively, for post-hoc Dunnthat coincides with the increased hIP-induced phosphorylation of
IKEPP, the role of the second messenger-regulated kinases PKA and
PKC on the agonist (cicaprost)-regulated interaction of IKEPP was
investigated (Fig. 6). As previous (Fig. 5A), while IKEPP was found in
the anti-HA.hIP immunoprecipitates from HEK.hIP cells under basal
conditions in the absence of agonist, the levels of IKEPP in the
immune-complexeswere signiﬁcantly increased in response to cicaprost
stimulation (Fig. 6, upper panel). Pre-treatment of HEK.hIP cells with ei-
ther the PKA inhibitor H-89 (10 μM, 10 min) or with the PKC inhibitor
Gö6983 (1 μM, 10 min) alone did not affect the level of IKEPP present
in the anti-HA.hIP immunoprecipitates either in the absence of agonist
or following cicaprost-stimulation (Fig. 6, upper panel). However, while
the basal interaction between the hIP and IKEPP was unaffected,
pre-incubation with both H-89 and Gö6983 together completely im-
paired the enhanced cicaprost-induced association of IKEPP in the
anti-HA.hIP complexes (Fig. 6, upper panel). In fact, in the presence of
H-89 and Gö6983, levels of IKEPP present in the hIP immune-
complexes were not signiﬁcantly different to those levels found in the
absence of cicaprost stimulation (Fig. 6).
Collectively, these data establish that the interaction of the hIP
with IKEPP/NHERF4 is modulated by agonist-induced activation of
the hIP which occurs, at least in part, through a mechanism involving
PKA and PKC-induced phosphorylation of IKEPP.
3.5. Localization of IKEPP and the hIP within the human kidney and
vascular endothelial cells
IKEPP was originally identiﬁed as an interactant of guanylyl cy-
clase C in a Y2H screen of a human intestinal cDNA library and its ex-
pression was subsequently determined to be restricted to the kidney,
small intestine and colon [7–9]. Prostacylin has long been known as
an important mediator of renal hemodynamics and expression of the
hIP has been detected in renal tubules [24,53,54]. Herein, in view of0
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Fig. 6. Involvement of PKA and PKC in the interaction between IKEPP and the hIP. HEK.hIP
cells, transiently transfected with plasmid encoding FLAG-tagged IKEPP, were pre-
incubated with vehicle, H-89 (10 μM) or Gö6983 (1 μM; Gö), either alone or in combina-
tion for 10 min, prior to stimulation for 10 minwith vehicle or cicaprost (1 μM;CICA). The
hIP was immunoprecipitated with anti-HA 101R and immunoprecipitates (IP) were
immunoblotted (IB)with anti-FLAG-IKEPP (upper panel) or anti-HA (3F10) antisera. Uni-
form expression of the FLAG-tagged IKEPP proteinwas veriﬁed by immunoblot analysis of
whole cell lysates (50 μg/lane) with anti-FLAG antibody (lower panel). The bar chart
showsmean relative levels of the IKEPP associatedwith the anti-HA 101R immunoprecip-
itates (relative protein, %±S.E.M., n=3) where levels in the absence of agonist are
expressed as 100%. The asterisks indicate that the levels of IKEPP found in anti-HA precip-
itates from cicaprost treated cells were signiﬁcantly increased compared to basal condi-
tions where **** indicates Pb0.0001.
2007H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012the novel interaction of IKEPP with the hIP, it was sought to examine
their expression in human kidney tissue sections. Immunohistochemi-
cal analysis, using a previously characterized, afﬁnity puriﬁed rabbit
polyclonal antibody directed to intracellular loop (IC)2 of the hIP [33],
conﬁrmed expression of the hIP in both the cortex and medulla regions
of the kidney, particularly in the epithelium lining the renal tubules
(Fig. 7A and Supplemental 2A; anti-hIP). Likewise, IKEPP was detected
in the epithelium lining of the tubules in both regions (Fig. 7A and
Supplemental 2A; anti-IKEPP). For example, in the renal cortex, intense
immunolabelling of both the hIP and IKEPP was observed in the distal
tubules, distinguished by their clear lumen (Fig. 7Ai and Supplemental
2Ai; upper insets), while in the proximal tubules the staining was less
intense (Fig. 7Ai and Supplemental 2Ai; lower insets). Hence, the hIP
and IKEPP localize in situ to the same cells within the human kidney.
As stated, prostacyclin and the IP play a critical role throughout
the vasculature, including in platelets, smooth muscle and in the vas-
cular endothelium [22]. Hence, having discovered a novel interaction
between the hIP and IKEPP, possible expression of IKEPP in cells de-
rived from the vascular endothelium was evaluated and, as a refer-
ence, compared to that in cell lines of the renal and GI system
where it is widely reported to be expressed. Consistent with previ-
ously published data [7,9], IKEPP is strongly expressed in cellular ex-
tracts from the renal HK2 and the intestinal Caco-2 cell lines (Fig. 7B),
where it migrates as a triplet, in keeping with the existence of multi-
ple isoforms of IKEPP [7]. In vascular endothelial cells, abundant ex-
pression of IKEPP was observed in both the immortalized human
endothelial EA.hy926 cell line and in primary (1°) human umbilical
vascular endothelial cells (HUVEC; Fig. 7B). It was noteworthy, in
the latter cell types, IKEPP was predominantly expressed as 2 closely
migrating protein isoforms that appeared to be identical in both
endothelial cells types but somewhat distinct from the predominant
species present in the HK and Caco-2 cells (Fig. 7B).Hence, given the abundant expression of IKEPP in the endothelial
cell lines, it was sought to determine if IKEPP may actually co-localize
and/or interact with the hIP in 1° HUVECs, a physiologically relevant
endothelial cell type. To this end, hIP endogenously expressed in 1°
HUVECs was immunoprecipitated, using the anti-hIP antibody [33],
and the presence of IKEPP in those immune-complexes was investi-
gated. IKEPP was readily detected in the anti-hIP, but not from IgG,
immunoprecipitates from 1° HUVECs (Fig. 7C, upper panel), con-
ﬁrming an interaction of IKEPP with the hIP. The failure to detect
IKEPP in the IgG precipitates was not due to the lack of IKEPP expres-
sion (Fig. 7C, lower panel). Furthermore, immunocytochemical analy-
sis of hIP and IKEPP expression in 1° HUVECs established that both
proteins show substantial co-localization where they are principally
expressed at the cell membrane with a small intracellular pool of
both proteins localized to the perinuclear area (Fig. 7D). Speciﬁcity
of the anti-hIP antisera was validated whereby pre-incubation of the
antiserum with the antigenic peptide, directed to the IC2 domain of
the hIP, speciﬁcally blocked immunodetection of the hIP (Supplemen-
tal Fig. 2B).
Taken together, these data establish that IKEPP and the hIP co-
localize in the kidney where they exhibit similar, differential staining
of the epithelial cells that line the proximal and distal tubules. Further-
more, it has also been established that IKEPP is abundantly expressed in
vascular endothelial cells, where it was found in immune-complexes
with the hIP. Collectively, these data identify a novel interaction of
IKEPP with the hIP and thereby suggest a possible functional role of
the interaction not only in the renal system but also in the vascular en-
dothelium where both proteins co-localize.
3.6. Effect of IKEPP on agonist-induced endothelial cell migration and
angiogenesis
The hIP has been previously implicated in both endothelial cell migra-
tion and angiogenesis [22]. More recently, the hIP was shown to play a
critical role in endothelial cell migration and in vitro angiogenesis/tube
formation in 1° HUVECs and these effects were greatly inﬂuenced by
the interaction of the hIP with PDZK1 [38]. Hence, given that PDZK1
and IKEPP are structurally and functionally related proteins coupled
with the demonstration herein that IKEPP is both expressed and present
in immune-complexes with the hIP in vascular endothelial cells, includ-
ing in 1° HUVECs, it was sought to investigate a possible functional role
of IKEPP on hIP-mediated endothelial cell migration and tube formation.
Initially, and consistent with our previous ﬁndings [38], stimulation of
1° HUVECs with the selective IP agonist cicaprost and, as a control,
with the pro-angiogenic mediator vascular endothelial growth factor
(VEGF) yielded signiﬁcant increases in endothelial cell migration
(Fig. 8A) andmean endothelial tube length, a measure of in-vitro angio-
genesis (Fig. 8C). To investigate the role of IKEPP in participating in the
observed endothelial cellmigration and tube formation, small interfering
RNA (siRNA) was used to disrupt its expression in 1° HUVECs. While
targeted knockdown of IKEPP had little effect on basal endothelial cell
migration or mean tube length, carried out in the presence of the drug
vehicle, it almost completely inhibited the cicaprost-induced increases
in both cellular processes (Fig. 8B andD; siRNAIKEPP). In contrast, disrup-
tion of IKEPP only marginally reduced VEGF-mediated cell migration
and mean tube length in 1° HUVECs (Fig. 8B and D; siRNAIKEPP) while
the scrambled control siRNACTRL had no signiﬁcant effect on either
basal-, VEGF- or cicaprost-induced migration or in vitro angiogenesis
(Fig. 8B and D; siRNACTRL). Moreover, immunoblot analysis conﬁrmed
that in the presence of siRNAIKEPP, endogenous expression of IKEPP in
1° HUVECs was reduced by more than 90% in all experiments (Fig. 8E).
Hence, consistent with previously reported ﬁndings [38], these
data reafﬁrm an essential role for the hIP in promoting endothelial
cell migration and angiogenesis/endothelial tube formation in vitro.
More critically, the data presented herein also establishes, for the
ﬁrst time, a role for IKEPP in mediating both cicaprost/IP-induced
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Fig. 7. Expression of IKEPP and hIP. Panel A: Consecutive formalin-ﬁxed, parafﬁn-embedded normal kidney sections were immunolabelled with anti-hIP and anti-IKEPP antibodies
prior to immunodetection using Vectastain Universal Elite ABC kit. Images were captured at 20× magniﬁcation using a Zeiss microscope and Axiovision software. The upper panels
(panel Ai) represent the renal cortex, where the insets represent 2-fold magniﬁcations of the indicated boxed regions corresponding to the distal (upper inset) and proximal (lower
inset) tubules, respectively. The lower panels (panel Aii) represent the renal medulla regions where the insets represent 2-fold magniﬁcations of the indicated boxed regions. Panel
B: Whole cell lysates (50 μg per lane) from human epithelial HK2, intestinal Caco-2, human endothelial EA.hy926 cells and 1° HUVECs (25 μg) were resolved by SDS-PAGE and
immunoblotted with anti-IKEPP and anti-HDJ2, where arrows indicate the presence of multiple IKEPP isoforms. Panel C: 1° HUVECs were immunoprecipitated with anti-hIP anti-
body or, as a control, with pre-immune IgG. Immunoprecipitates (IP) were immunoblotted (IB) with anti-IKEPP (upper panel). Expression of endogenous IKEPP was veriﬁed by
immunoblot analysis of whole cell lysates (50 μg/lane) with anti-IKEPP antibody (lower panel). Panel D: 1° HUVECs were immunolabelled with anti-hIP or anti-IKEPP antibodies
prior to detection with AlexaFluor488 goat anti-rabbit secondary antibody. Images were captured at 63× magniﬁcation using a Zeiss microscope and Axiovision software.
2008 H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012endothelial migration and in vitro angiogenesis in 1° HUVECs and
thereby reveal a clear functional link between the hIP and IKEPP
within the vasculature.
4. Discussion
We recently identiﬁed an interaction between the hIP and PDZK1,
the third member of the NHERF family of multi-PDZ domain proteins
[38]. Herein, we report that the hIP also interacts with the NHERF4
family member IKEPP. In both cases, the extreme carboxyl-terminal
residues of the hIP were identiﬁed as a Class I PDZ ligand [3], whereresidues at the P0 (Cys386) and P-2 (Ser384) positions of the PDZ ligand
are essential for the interactions. However, as stated, the hIP is unusu-
al among GPCRs in that it undergoes farnesylation within its evolu-
tionarily conserved −C383SLC386 motif [30,31] while data herein are
consistent with recent ﬁndings that this ‘CaaX’ motif also acts as a
PDZ ligand [38]. While several lines of evidence indicated that the in-
teraction of the hIP with IKEPP is independent of the isoprenylation
status of the receptor, follow-up studies involving more direct bio-
physical approaches are necessary to ascertain which form(s) of the
hIP, whether it be the immature, unprocessed (−CSLC) and/or the
farnesylated, fully processed forms, that interacts with IKEPP, includ-
ing for determination of the relative binding afﬁnities.
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Fig. 8. Effect of IKEPP on hIP agonist-induced migration and tube formation in 1° HUVECs. Migration (panels A and B) and tube formation (panels C and D) by primary (1°) HUVECs
were analyzed at 0 h and 12 h in following incubation with drug vehicle, VEGF or cicaprost, as indicated, in either non-transfected cells (panels A and C) or in cells transfected
with siRNACTRL or siRNAIKEPP (panels B and D), where immunoblot analysis conﬁrmed speciﬁc disruption of IKEPP expression (panel E). Bar charts represent mean fold increases
(±S.E.M.; n=3) in either wound closure or tube length in the presence of vehicle, VEGF or cicaprost, as indicated, at 12 h. The asterisks indicate either signiﬁcant
agonist-induced increases in migration (panels A and B) or signiﬁcant agonist-induced increases in tube length (panels C and D) in comparison to vehicle-treated cells where **,
and *** indicate Pb0.01, and Pb0.001, respectively, for post hoc Dunnett's multiple comparison t-test analysis.
2009H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012The ability of the hIP to bind both PDZK1 and IKEPP is not unusual
as several other proteins can bind multiple NHERF family members
[4,10,12,55]. Furthermore, while the hIP preferentially binds to
PDZD3, PDZD4 and PDZD1, but not to PDZD2, of PDZK1 [38], it binds
to PDZD1 and, to a lesser extent, PDZD2 but not to PDZD3 or PDZD4 of
IKEPP. These data clearly indicate highly speciﬁc structural require-
ments in determining the molecular interactions of the hIP with
PDZK1 and with its related IKEPP. Similarly, the organic cation trans-
porter OCT/OCTN family members, OCTN1 and OCTN2, display differ-
ent binding preferences for PDZ domains within PDZK1 and IKEPP
where both OCTN proteins bind to PDZD1, PDZD2 and PDZD4 of
PDZK1 but bind to PDZD1 and PDZD3 of IKEPP [13,56,57]. In the case
of OCTN2, in addition to the different structural requirements for its
interaction with IKEPP and PDZK1, it has also been established that
it may be differentially regulated by the 2 NHERF members whereby
IKEPP mediates cell surface stabilization of OCTN2 while PDZK1 acts
to increase its cation transport activity [13,56]. Herein, IKEPP was
found to increase the functional expression of the hIP, as evidenced
by the enhanced ligand binding and agonist-induced cAMP genera-
tion, but did not affect the overall level of hIP expression per se. In
contrast to this, in the case of PDZK1, it led to substantial increases
in hIP expression levels at the cell surface, as well as increasing its
functional expression [38]. These data suggest that, similar to thatreported for other interactants [13,56], PDZK1 and IKEPP display
clear structural and functional differences in their interaction and
regulation of the hIP.
Agonist-activation plays an important role in modulating the sig-
naling pathways of members of the GPCR superfamily through modu-
lation of their interaction(s) with speciﬁc GIPs including in the case of
the hIP with its GIPs [33,34,44]. We recently established that the
interaction of the hIP with PDZK1 is also dynamically regulated in
response to receptor activation and that this occurs through a mecha-
nism involving hIP-mediated cAMP-dependent PKA phosphorylation
of PDZK1 at Ser505, within its C-terminal regulatory region [38]. Here-
in, it was established that IKEPP interacts constitutively with the
hIP but that, at 10 min post-agonist activation, this interaction is sub-
stantially increasedwhich coincideswith increased hIP-induced phos-
phorylation of IKEPP on Ser residue(s). Furthermore, while inhibition
of the second-messenger kinases PKA or PKC alone did not affect the
cicaprost-regulated interaction, inhibition of both kinases together
completely abrogated the enhanced agonist-induced interaction of
IKEPP with the hIP. The suggestion that IKEPP may be phosphorylated
at multiple sites by more than one kinase is not without precedence.
Within the NHERF family, while NHERF2 is not phosphorylated [4]
and PDZK1 is only known to be phosphorylated at Ser505 [51], multiple
phosphorylation events have been identiﬁed for NHERF1 [58]. For
2010 H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012example, NHERF1 is phosphorylated by both PKA and PKC even
though it is devoid of canonical PKA or PKC phosphorylation motifs
[59]. Moreover, it is phosphorylated by PKC and other kinases to
modulate its oligomerization and inﬂuence its protein complex forma-
tion [5]. While our studies suggest that IKEPP may be phosphorylated
at Ser residue(s) by both PKA and PKC in response to agonist-
activation of the hIP, they do not identify the speciﬁc phosphorylated
residues nor do they exclude the possibility that other kinase(s) and/
or phospho-targeted residue(s), such as at Thr or Tyr, may also be
involved. None the less, as stated, inhibition of both PKA and PKC to-
gether completely impaired the enhanced agonist-induced interac-
tion of IKEPP with the hIP suggesting key roles for those second
messenger-regulated kinases in the modulated interaction. While ef-
forts involving bioinformatics along with mutational studies were
made herein to pin-point the actual residues within IKEPP that are
phosphorylated in response to hIP activation, owing to the very
many potential phospho-target sites that occur within IKEPP, it was
not possible to categorically identify those target sites (data not
shown). Consistent with this, Thelin et al. have evidence of at least 6
potential phosphorylation sites within IKEPP [5]. Hence, additional
studies are required to identify the target sites of phosphorylation
and to investigate the true implications of the regulated IKEPP interac-
tion for hIP function including consideration of dynamic interactions
following more prolonged agonist-stimulation [38].
IKEPP was originally identiﬁed in the kidney and also found in the
small intestine and colon but, to our knowledge, its expression has not
been detected in any other tissue types to date [5,7,8]. Through its
regulation of key interacting partners, IKEPP has roles in the renal and
gastrointestinal systems in anion secretion [7], calcium secretion [9]
and carnitine transport [56]. As stated, prostacyclin is widely implicated
in the regulation of renal hemodynamics and expression of the hIP hasIKEPP 
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Fig. 9. Model of the interaction between the hIP and IKEPP. In the absence of agonist, both
interactions are largely dependent on PDZ domain 1 (PDZD1), and to a lesser extent PDZD2, o
Upon cicaprost stimulation (10 min; CICA), the association of IKEPP and PDZK1 with the hI
enhanced in response to receptor activation, an effect that is abrogated by the selective IP an
Gö6983, respectively. On the other hand, in response to cicaprost (10 min) stimulation, th
hIP-induced PKA phosphorylation of Ser505 within the C-terminal regulatory domain of IKE
motes endothelial cell migration and tube formation, a measure of in vitro angiogenes
siRNA-mediated targeted disruption of both IKEPP and PDZK1 [38] expression speciﬁcally ibeen detected in renal tubules of the inner and outermedulla and of the
cortex [24,25,53]. Furthermore, prostacyclin is increasingly implicated
in regulating renin release and in the development of renovascular
hypertension-associated with obstructive vascular disease, including
atherosclerosis [17,60–62]. Herein, we demonstrate that IKEPP and
the hIP colocalize to the epithelial lining of the distal and, to a lesser
extent, the proximal renal tubules, pointing to a potential role for the in-
teraction of the hIPwith IKEPP in renal hemodynamics. In addition, con-
sistent with the discovery of the expression of the IKEPP in vascular
endothelial cells, it was established that it co-localizes with the hIP; is
found therein in immune-complexeswith the hIP and that, functionally,
it plays a key role in hIP-mediated endothelial cell migration and in vitro
angiogenesis. To the best of our knowledge, this is theﬁrst evidence that
IKEPP is expressed outside of the renal and gastrointestinal systems and
theﬁrst indication of a functional role for IKEPP in the vascular endothe-
lium. While our studies were carried out in vascular endothelial cells,
it will be of substantial interest to investigate the interplay between
IKEPP and the IP within the renal vasculature and whether alterations
in that interaction may contribute to the role of the IP in renovascular
hypertension-associated with obstructive vascular disease.
Based on data generated herein and from our previous study involv-
ing PDZK1 [38], we present amodel of the agonist-regulated interaction
of IKEPP and PDZK1with the hIP (Fig. 9), in addition to the role of these
2 closely related, but structurally and functionally distinct, NHERF
members for prostacyclin regulated endothelial cell migration and in
vitro angiogenesis. Under basal conditions, in the absence of agonist,
both IKEPP and PDZK1 are constitutively associated in complexes with
the hIP, where PDZD1 of IKEPP and PDZD3 PDZK1 are the preferential
binding domains, respectively. While both IKEPP and PDZK1 [38] are
phosphorylated in response to agonist (cicaprost)-activation of the
hIP, an effect that is blocked by the selective IP antagonist RO1138452,PDZK1
l Cells
ed 
tion &
genesis
siRNAPDZK1
RO1138452
H89
IKEPP and PDZK1 are constitutively associated in a complex with the hIP where these
f IKEPP, and PDZD3, and to a lesser extent PDZD1 and PDZD4, of PDZK1 [38], respectively.
P is differentially modulated. More speciﬁcally, the association of IKEPP with the hIP is
tagonist RO1138452 and the combined activity of the PKA and PKC inhibitors, H-89 and
ere is a transient disassociation of PDKZ1 from the hIP complex and this occurs due to
PP [38]. Herein, and previously [38], it was established that cicaprost stimulation pro-
is, and that these effects are impaired by the selective IP antagonist RO1138452.
mpairs cicaprost-induced endothelial cell migration and in vitro angiogenesis.
2011H.M. Reid et al. / Biochimica et Biophysica Acta 125 (2012) 1998–2012their interaction with the hIP appears to be differentially modulated.
More speciﬁcally, in response to agonist-activation of the hIP, there
is an initial transient dissociation of PDZK1 from the hIP complex
[38] while, in contrast to this, there is an initial increase in the inter-
action of IKEPP with the activated hIP (Fig. 6). In the case of PDZK1,
the agonist-regulated interaction involves direct hIP-induced cAMP-
dependent PKA phosphorylation of PDZK1, where Ser505 within its
C-terminal regulatory domain was identiﬁed as the speciﬁc phos-
photarget [38]. On the other hand, inhibition of both PKA or PKC are
necessary to impair the agonist-regulated interaction between IKEPP
with the hIP suggesting that activation of the cAMP- and inositol
phosphate-signaling cascades of the hIP are necessary to modulate its
interaction with IKEPP [28,30]. Furthermore, as stated, evidence of
an interaction between the hIP and IKEPP endogenously expressed
in vascular endothelial cells (1° HUVECs) was conﬁrmed through
both co-immunoprecipitation and immunocytochemical approaches
(Fig. 7C and D, respectively) and that this interaction occurs constitu-
tively, in the absence of agonist. While beyond the remit of the current
study, it will be of interest to investigate the inﬂuence of cicaprost on
the interaction and co-localization of the hIP and IKEPP within the vas-
cular endothelium and, more speciﬁcally, whether the interaction is
regulated in an agonist-dependent manner. Consistent with their func-
tional expression in vascular endothelial cells, siRNA‐targeted disrup-
tion of both PDZK1 [38] and IKEPP was found to speciﬁcally impair
prostacyclin-induced endothelial cell migration and in vitro angiogene-
sis. Taken together, our ﬁndings establish a role for IKEPP in the vascu-
lature where it regulates hIP-mediated endothelial migration and
angiogenesis.
The discovery that the hIP interacts with both PDZK1 and IKEPP,
NHERFproteins that showbothover-lappingbut also distinct (i) patterns
of expression, (ii) interacting partners coupled with key (iii) structural
and (iv) functional differences, reveals further insights into the factors
regulating this complex ‘I prostanoid receptor’. Furthermore, detailed in-
vestigation of the functional interplay of the two NHERFmembers in the
regulation of the hIP should lead to signiﬁcant new insights into the role
of this important receptor and of those PDZ adapter proteins within the
vascular, renal, gastrointestinal and pulmonary systems where they
and their key interacting partners are most abundantly expressed.Acknowledgements
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